UCHL5抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07931(UCHL5 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07931(UCHL5 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The UCHL5 antibody is a crucial tool for studying the ubiquitin carboxyl-terminal hydrolase L5 (UCHL5), a deubiquitinating enzyme (DUB) involved in regulating protein turnover via the ubiquitin-proteasome system. UCHL5. also known as UCH37. selectively removes ubiquitin chains from substrates, enabling precise control of protein degradation. It associates with the proteasome through binding to RPN13. facilitating substrate processing and recycling of ubiquitin. UCHL5 plays dual roles in cancer, acting as either an oncogene or tumor suppressor depending on cellular context, and is implicated in DNA repair, cell cycle regulation, and apoptosis. Dysregulation of UCHL5 has been linked to malignancies, neurodegenerative disorders, and immune diseases.

UCHL5 antibodies are widely used in research to detect protein expression, localization, and functional interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These antibodies help elucidate UCHL5's mechanistic roles in disease pathways and its potential as a therapeutic target. Commercially available antibodies are typically raised against specific epitopes of human UCHL5. with validations ensuring specificity for experimental accuracy. Ongoing studies focus on developing UCHL5 inhibitors, underscoring the antibody's importance in both basic research and drug discovery.